⏰ This approach can help customers move to clinical trials 8 months faster than the standard approach.
💡 The global approach offers both speed and savings, with analytical facilities in the US and Europe.
🔬 The approach overcomes problems with multiple external suppliers for production and analytics.
🧬 AAVelocity and Lentisure are available for scalable viral vector and lentivirus production, along with plasmid production and cell line development.
💪 By controlling all manufacturing parts, SK pharmteco aims to reduce time and offer cost-effective solutions.
🏆 This platform helps address challenges in the gene and cell therapy industry and secure investment.
Introduction:
The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process that can help customers move to clinical trials faster and more efficiently. Adrien Auffret-Cariou, team lead process development projects at Yposkesi, a SK pharmteco company, presented this global approach at a recent conference on Advanced Therapies. The approach offers speed and savings by providing analytical facilities in the United States and Europe and avoiding the use of multiple external suppliers.
- The new global approach to standardized viral vector manufacturing offers speed and savings.
- The approach overcomes the challenges of using multiple external suppliers for production and analytics.
- AAVelocity, a standardized scalable approach to manufacturing adeno-associated viruses (AAV), and Lentisure, for scalable lentivirus production, are among the offerings.
- Customers benefit from a single source for viral vector and plasmid manufacturing, which saves time and improves planning efficiency.
- The global approach is particularly valuable for companies in the gene and cell therapy industry who are under pressure to move quickly to clinical trials.
Conclusion:
The SK pharmteco group is revolutionizing viral vector and plasmid manufacturing with its standardized global approach. By offering a single source for manufacturing and analytics, this approach saves time, improves efficiency, and allows for faster movement to clinical trials. This is particularly valuable for companies in the gene and cell therapy industry who face tight timelines and pressures for quick results.
